Stock BOT BOTANIX PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Botanix Pharmaceuticals Limited

Equities

BOT

AU000000BOT2

Pharmaceuticals

Market Closed - Australian S.E.
Other stock markets
 02:11:03 2024-06-07 am EDT 		5-day change 1st Jan Change
0.275 AUD -1.79% Intraday chart for Botanix Pharmaceuticals Limited -5.17% +44.74%
May. 21 Evans & Partners Starts Botanix Pharmaceuticals at Speculative Buy With AU$0.55 Price Target MT
May. 13 Euroz Hartleys Adjusts Botanix Pharmaceutical’s Price Target to AU$0.33 From AU$0.30, Keeps at Speculative Buy MT

Valuation

Fiscal Period: June 2019 2020 2023 2024 2025 2026
Capitalization 1 139.3 37.94 170.6 433.2 - -
Enterprise Value (EV) 1 139.3 37.94 170.6 -9,167 -1,867 -27,767
P/E ratio -8.04 x -2.18 x -16.5 x -27.5 x 27.5 x 9.17 x
Yield - - - - - -
Capitalization / Revenue 29 x 4.9 x - 0.54 x 0.01 x 0 x
EV / Revenue 29 x 4.9 x - -11.5 x -0.06 x -0.31 x
EV / EBITDA -8.18 x -2.31 x - 0.78 x -0.17 x -0.43 x
EV / FCF -10.6 x -2.17 x - 0.93 x - -
FCF Yield -9.44% -46% - 108% - -
Price to Book 22.8 x 1.6 x - - - -
Nbr of stocks (in thousands) 774,028 972,698 1,312,460 1,575,137 - -
Reference price 2 0.1800 0.0390 0.1300 0.2750 0.2750 0.2750
Announcement Date 8/19/19 8/31/20 8/31/23 - - -
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2019 2020 2023 2024 2025 2026
Net sales 1 4.811 7.744 - 800 30,500 89,200
EBITDA 1 -17.03 -16.41 - -11,700 10,900 64,200
EBIT 1 -17.03 -16.51 - -11,800 10,800 63,900
Operating Margin -354.04% -213.25% - -1,475% 35.41% 71.64%
Earnings before Tax (EBT) 1 -17.04 -16.73 - -11,700 10,900 64,000
Net income 1 -17.04 -16.73 -9.154 -11,700 9,300 48,000
Net margin -354.15% -216.04% - -1,462.5% 30.49% 53.81%
EPS 2 -0.0224 -0.0179 -0.007900 -0.0100 0.0100 0.0300
Free Cash Flow 1 -13.15 -17.45 - -9,900 - -
FCF margin -273.4% -225.31% - -1,237.5% - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 8/19/19 8/31/20 8/31/23 - - -
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2020 2023 2024 2025 2026
Net Debt 1 - - - - - -
Net Cash position 1 - - - 9,600 2,300 28,200
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -13.2 -17.4 - -9,900 - -
ROE (net income / shareholders' equity) -202% -138% - -37.6% 21.2% 66.2%
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share 0.0100 0.0200 - - - -
Cash Flow per Share - - - - - -
Capex 1 - - - - 800 2,200
Capex / Sales - - - - 2.62% 2.47%
Announcement Date 8/19/19 8/31/20 8/31/23 - - -
1AUD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.275 AUD
Average target price
0.55 AUD
Spread / Average Target
+100.00%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
BOTANIX PHARMACEUTICALS LIMITED Stock Botanix Pharmaceuticals Limited
+44.74% 285M
MERCK KGAA Stock Merck KGaA
+19.29% 80.5B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+15.08% 9.15B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-18.33% 4.9B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+43.39% 4.49B
YUHAN CORPORATION Stock Yuhan Corporation
+13.95% 4.44B
INDIVIOR PLC Stock Indivior PLC
+10.89% 2.19B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-28.40% 2.13B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+15.93% 2.1B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-43.17% 1.78B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BOT Stock
  4. Financials Botanix Pharmaceuticals Limited